You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a Nrf2 activator for the treatment of scleroderma
SBC: CUREVEDA, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes
SBC: Jenesis Biosciences LLC Topic: NIDDKDESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Intravesical Liposomes for Interstitial Cystitis
SBC: Lipella Pharmaceuticals Inc. Topic: NIDDKDESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Intravesical Liposomes for Interstitial Cystitis
SBC: Lipella Pharmaceuticals Inc. Topic: NIDDKDESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to e ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema
SBC: ADEPTHERA, LLC Topic: NCIDESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are mini ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development and in vitro validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 105DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development and wear testing of bi-material bearing surfaces for hip arthroplasty
SBC: CORNERSTONE PARTNERS, LLC Topic: NIADESCRIPTION (provided by applicant): Hip replacement surgery is a tremendously effective and successful treatment for patients suffering from degenerative joint disease. However, revision surgery accounts for about 13% of hip implant surgeries in the U.S.,costing 3 billion annually and presenting significantly increased morbidity and risk of complication for patients. Wear and/or failure of total ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a clinical hemoglobin modulator
SBC: Phoenicia Biosciences, Inc. Topic: NHLBIDESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppres ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antigen Capture Assay for Babesia microti
SBC: BIOPEPTIDES CORP Topic: NIAIDDESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health